



"In³ Europe: A Preview of Early-Stage Medtech Companies"

September 20-21, 2005 · Brussels, Belgium
Crowne Plaza Hotel, Brussels City Centre

medtech *W* insight
a division of Windhover Information

Vascular Reconditioning: Interventional Vascular Therapists Need More than Drug-Eluting Stents

by Ronald C. Trahan

Vascular Reconditioning Inc. ("VRI") is pioneering development of the world's first combined drug/device intervention designed to selectively target a major underlying cause of heart attacks in patients with coronary heart disease (CHD). VRI is collaborating closely with Cardiovascular Research Foundation (CRF) on development of this novel interventional technology and is in the midst of establishing the Company's technical resources alongside CRF's new preclinical interventional research facility in Orangeburg, N.Y. "We are seeking \$5 million in Series A funding to demonstrate proof of efficacy and safety in an animal model of atherosclerosis as a foundation to transition into clinical development in patients with CHD," says Nick Yeo, VRI's President and CEO. Yeo has nearly 30 years of experience in international pharmaceutical and medical device businesses. Prior to joining VRI, he spent five years with Light Sciences Corporation (LSC), initially as VP of Product Development, during which time LSC successfully filed its first oncology IND, and subsequently as VP of Strategic Business Development. **"VRI**



Nick Yeo
President and CEO,
Vascular Reconditioning

bypasses the 'vulnerable plaque' treasure hunt," explains Yeo. "While the search for vulnerable plaque may have become the holy grail of interventional cardiology, **vascular reconditioningSM** neatly bypasses the dilemma of trying to adapt the existing, focally-based interventional tool kit to treatment of a multifocal, systemic disease," Yeo says. "Focal treatments need diagnostic imaging to pre-localize and risk-stratify individual sites of vulnerability for focal intervention. On the other hand, vascular reconditioning—by closing leaky neovascularization (abnormal growth of fragile blood vessels) only where it occurs—in, and around, the plaque—provides a basis for treating either single-vessel or regional disease in patients at risk of acute coronary syndromes—but without the need to pre-localize the vulnerable plaque. Today's interventional vascular therapist needs more than just drug-eluting stents." (While need in the interventional treatment of angina in patients with CHD has been largely fulfilled by the advent of drug-eluting stents, medical need for therapeutic innovation to manage CHD patients at risk of acute coronary syndromes is still desperately needed.) "By specifically targeting treatment to an underlying cause of atherosclerotic plaque progression and instability," adds Yeo, *"vascular reconditioning* is designed to provide interventional vascular therapists with a unique approach to stabilize atherosclerotic disease in at-risk patients."

Vascular Reconditioning's Chief Scientific Officer and Chairman of its Scientific Advisory Board is Martin ("Marty") B. Leon, M.D., a practicing interventional cardiologist at New York-Presbyterian Hospital/Columbia University Medical Center and Chairman of the Cardiovascular Research Foundation. Dr. Leon has co-authored more than 900 publications, has performed over 7,000 interventional procedures, and is Director of Transcatheter Cardiovascular Therapeutics ("TCT"), the world's largest scientific meeting dedicated to interventional vascular therapy.

"We are very much looking forward to presenting at Medtech Insight's first In³ meeting in Brussels. Medtech Insight's In³ conferences always attract top-shelf investors, including business development executives from major companies in the industry. We fully expect to attract meaningful attention from investors at the Brussels venue," says Yeo.

What leading professionals are saying about Medtech Insight's In³ events:



"Medtech Insight's investor conference format provides a well-organized process, if you will, in which to explore numerous possibilities. In one place you can find dozens of potentially disruptive technologies, and readily determine which ones intersect with your investment objectives."

Chris Stenzel
Senior Vice President
Kaiser Permanente Ventures



"I participate at Medtech Insight meetings as an end-user hospital that is looking to stay at the cutting-edge of upcoming breakthroughs in medical technology. My organization has purchased several technologies based on information I obtained through Medtech Insight meetings."

Joyce Chavez, R.N.
Clinical Resource Manager
Hoag Memorial Hospital Presbyterian



"I make it a point to attend Medtech Insight's conferences because I can efficiently validate what I know to be at the cutting-edge in medical technology. I must maximize the time I spend staying on top of emerging companies, and Medtech Insight meetings make it simple for me to do so."

Jeffrey Barnes
General Partner
Oxford Bioscience Partners

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small companies, both public and private.

Investment In Innovation (In³) Europe: A Preview of Early-Stage Medical Technology Companies Crowne Plaza Hotel, Brussels City Centre, Brussels, Belgium, September 20-21, 2005

Medtech Insight's In³ conferences have drawn a total of more than 4,600 senior execs from the investment community and major medtech companies, and have featured more than 540 innovative early-stage presenting companies. In³ Europe will feature a new group of over 50 early-stage medical technology companies from around the world seeking partnering and/or investment.

To register for this conference, please call 949-219-0150 or 888-290-2225 (toll-free in the U.S.), send an email to in3@medtechinsight.com, or register online at www.medtechinsight.com.